Overview

Open Study to Evaluate the Safety of Levocetirizine in Young Children (2 - 6 Years) Suffering From Allergic Rhinitis

Status:
Completed
Trial end date:
2004-12-01
Target enrollment:
Participant gender:
Summary
4 week open study to evaluate the safety of levocetirizine in young children (2 - 6 years) suffering from allergic rhinitis. As secondary objective, this study will assess the efficacy of the treatment by means of the T4SS (Total 4 symptoms scores of allergic rhinitis) and each of the 4 individual rhinitis symptom scores
Phase:
Phase 2
Details
Lead Sponsor:
UCB Pharma
Treatments:
Cetirizine
Levocetirizine
Pharmaceutical Solutions